OR WAIT 15 SECS
The agency and the European Commission published updated guidance to answer questions about Brexit.
On Dec. 1, 2017, the European Medicines Agency (EMA) and the European Commission published updated guidance for pharmaceutical companies regarding the United Kingdom’s withdrawal from the European Union. The new guidance answers additional questions about marketing applications and authorizations.
New in this update is more information on batch release sites located in the UK, which must be located in the EU; the effect on herbal medicinal products; and applications for orphan drug designation. The guidance also discusses the local representatives in the UK mentioned in product information, global marketing, and the sunset clause.